SOUTH PLAINFIELD, N.J., July 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotionof Joseph McIntosh, M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's portfolio.
"Dr. McIntosh's extensive experience
Dr. McIntosh joined PTC Therapeutics, Inc. in 2015 as Vice President, Clinical Development where he has been the lead clinician within the development group. Prior to joining PTC, Dr. McIntosh was Executive Director of Clinical Development of NPS Pharmaceuticals, responsible for managing and successfully coordinating cross functional program teams. Prior to NPS, he worked for Pfizer and Eisai where he assumed the role of clinical lead and program team lead for variety of development programs. Over the last several years, Joe has worked exclusively on rare diseases where he has led several development programs across hematology, hepatic and gastrointestinal therapeutic areas which include the successful initiation and completion of multiple phase 3 programs. Dr. McIntosh holds a medical degree from University of Witwatersrand, JHB, South Africa.
About PTC Therapeutics PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding nearly 20 years ago, PTC's mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and its corporate headquarters is located in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.
For More Information:
Investors:Emily Hill+ 1 (908) email@example.com
Media:Jane Baj+1 (908) firstname.lastname@example.org
Forward-Looking Statements:All statements, other than those of historical fact, contained in this release are forward-looking statements, including statements regarding PTC's strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-promotion-of-dr-joseph-mcintosh-to-senior-vice-president-and-head-of-clinical-development-300493076.html
SOURCE PTC Therapeutics, Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All